ArticleCancer immunology, immunotherapy : CII2023

Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy.

Camilla Rydberg Millrud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.